Today's Rundown Featured Story | | | Friday, June 29, 2018 Acceleron Pharma and partner Celgene unveiled data showing luspatercept reduced the need for red blood cell transfusions in patients with myelodysplastic syndromes. |
|
|
Top Stories Friday, June 29, 2018 Four months after Voyager Therapeutics’ chief and founder Steven Paul, M.D., said he would step down to become an “executive science adviser,” the neurological disease biotech has found a new leader. Friday, June 29, 2018 AbbVie has dumped one of Galapagos’ cystic fibrosis regimens after getting a look at underwhelming clinical data on a component of the triple combination. The action prompted Galapagos to review the future of its relationship with AbbVie—and provided a boost to cystic fibrosis rival Vertex. Monday, June 25, 2018 The increasing demand for innovation in research and the related pressures to deliver on the most promising findings from discovery are also driving the need for simultaneous innovation in the technologies that enable that innovation and, likewise, the reliance on data management solutions that respond to an increasingly complex scientific environment. Friday, June 29, 2018 The FDA has lifted a clinical hold on Aptose Biosciences’ APTO-253 almost three years after it stopped the blood cancer program. Aptose is now racing to resume dosing patients with the c-Myc inhibitor in the paused phase 1b study. Friday, June 29, 2018 Shares in Gemphire Therapeutics more than doubled after its lead drug gemcabene aced a midstage trial in patients with high triglycerides, setting up a phase 3 program. Thursday, June 28, 2018 In this week's EuroBiotech Report, Nanobiotix soars on cancer data, Novo Holdings backs NDE, Boehringer makes a plant investment and more. Friday, June 29, 2018 Investors question Takeda CEO over the competitiveness of Shire's hemophilia products; the FDA clears Biocon's biosimilars plant key to the company's partnerships with Mylan and Sandoz; China's C-Bridge Capital has invested $35 million in Nuance Biotech; and more. Friday, June 29, 2018 An executive shakeup at Johnson & Johnson leaves Duato with the largest portfolio; Genentech's Sabry will take on global partnering for Roche; Neos poaches AgeneBio chief as its CEO abruptly resigns; and Portola hires a former Genentech executive to oversee manufacturing after delays. These moves, plus more hirings, firings and retirings throughout the industry. Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented By: Covance A solid RBM plan will not only help you comply with the ICH guidelines, but will help you mitigate risks which could ultimately delay your trials and increase costs. Download today! Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. |
|
